LIVZON PHARMAC. GRP H YC1 (LP6) - Total Assets
Based on the latest financial reports, LIVZON PHARMAC. GRP H YC1 (LP6) holds total assets worth €24.19 Billion EUR (≈ $28.29 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LIVZON PHARMAC. GRP H YC1 - Total Assets Trend (2021–2025)
This chart illustrates how LIVZON PHARMAC. GRP H YC1's total assets have evolved over time, based on quarterly financial data. Also see LP6 market cap for the company's overall valuation and market capitalisation.
LIVZON PHARMAC. GRP H YC1 - Asset Composition Analysis
Current Asset Composition (December 2025)
LIVZON PHARMAC. GRP H YC1's total assets of €24.19 Billion consist of 67.2% current assets and 32.8% non-current assets. Review debt load of LIVZON PHARMAC. GRP H YC1 to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 38.8% |
| Accounts Receivable | €2.25 Billion | 9.4% |
| Inventory | €1.56 Billion | 6.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €833.72 Million | 3.5% |
| Goodwill | €124.91 Million | 0.5% |
Asset Composition Trend (2021–2025)
This chart illustrates how LIVZON PHARMAC. GRP H YC1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See LP6 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LIVZON PHARMAC. GRP H YC1's current assets represent 67.2% of total assets in 2025, an increase from 65.6% in 2021.
- Cash Position: Cash and equivalents constituted 38.8% of total assets in 2025, down from 40.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 9.4% of total assets.
LIVZON PHARMAC. GRP H YC1 Competitors by Total Assets
Key competitors of LIVZON PHARMAC. GRP H YC1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
LIVZON PHARMAC. GRP H YC1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.96 | 2.28 | 1.81 |
| Quick Ratio | 1.77 | 2.01 | 1.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €7.67 Billion | €9.23 Billion | €7.81 Billion |
LIVZON PHARMAC. GRP H YC1 - Advanced Valuation Insights
This section examines the relationship between LIVZON PHARMAC. GRP H YC1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.42 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -1.9% |
| Total Assets | €23.99 Billion |
| Market Capitalization | $757.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values LIVZON PHARMAC. GRP H YC1's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: LIVZON PHARMAC. GRP H YC1's assets decreased by 1.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for LIVZON PHARMAC. GRP H YC1 (2021–2025)
The table below shows the annual total assets of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €23.99 Billion ≈ $28.04 Billion |
-1.92% |
| 2024-12-31 | €24.46 Billion ≈ $28.59 Billion |
-2.35% |
| 2023-12-31 | €25.04 Billion ≈ $29.28 Billion |
+0.71% |
| 2022-12-31 | €24.87 Billion ≈ $29.07 Billion |
+11.16% |
| 2021-12-31 | €22.37 Billion ≈ $26.16 Billion |
-- |
About LIVZON PHARMAC. GRP H YC1
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more